DexCom Inc (DXCM) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Total Assets Chart for DexCom Inc
DexCom Inc (DXCM) total assets for FY2025 were USD 6.3B, a -2.2% change from FY2024. DexCom Inc's total assets grew from USD 14.4M in 2000 to USD 6.3B in 2025 (44043.6% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 8.1%, 10-year CAGR of 36.0%, 20-year CAGR of 26.6%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $31.19B
- Implied Share Price
- $82.66
- Enterprise Value
- $32.26B
- Revenue (TTM)
- $4.97B
- EBITDA
- $1.40B
- Profit Margin
- 20.12%
- Trailing P/E
- 32.67
- Forward P/E
- 34.36
- Price/Book (MRQ)
- 12.52
- Price/Sales (TTM)
- 6.30
- EV/EBITDA
- 20.69
- EV/Revenue
- 6.49
- Dividend Yield
- —
- Book Value
- $6.95
- Free Cash Flow (FY2025)
- $1.08B
- Free Cash Flow Yield
- 3.45%
Snapshot as of 5th August 2026 — not point-in-time controlled, may lag the live market by a few days.